| P2093 | author name string | John N van den Anker | |
| | Matthijs de Hoog | |
| P2860 | cites work | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates | Q24244642 |
| | Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis | Q35297198 |
| | Therapeutic drug monitoring of aminoglycosides in neonates | Q37409465 |
| | Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring | Q40640328 |
| | Risk factors of sensorineural hearing loss in preterm infants | Q42551597 |
| | Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss | Q44273563 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Renal function in premature infants during aminoglycoside therapy | Q72343532 |
| P433 | issue | 5 | |
| P304 | page(s) | 343-4; author reply 344-5 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Therapeutic drug monitoring of aminoglycosides in neonates | |
| P478 | volume | 48 | |